ConCallIQ
Go Pro
APOLLO Diversified 12 Nov 2025

Apollo Micro Systems Limited — Q2 FY26

Apollo Micro Systems delivered a stellar Q2 FY26 with revenue of ₹225 crore, up 69% QoQ, and PAT of ₹30 crore, up 70% QoQ, driven by robust order book execution and transition of multiple products into production.

bullish high
Compare with...
Revenue ₹225 Cr
EBITDA ₹59 Cr
PAT ₹30 Cr
EBITDA Margin 26.3%
Duration 63 min
Read Time 1 min read

Financial stats pending filing verification

2-Minute Summary

✦ AI-Generated from Full Transcript

Apollo Micro Systems delivered a stellar Q2 FY26 with revenue of ₹225 crore, up 69% QoQ, and PAT of ₹30 crore, up 70% QoQ, driven by robust order book execution and transition of multiple products into production. EBITDA margin came in at 26.3%, reflecting operational discipline. Management reiterated a 45-50% CAGR revenue growth guidance for FY26-27, backed by a healthy order book (~₹800 crore) and upcoming large programs (MIGM, QRSAM, ESWT). Unit 3 capex of ₹250 crore is on track, with full production expected by Q1 FY27, expanding capacity 8x. Risks include potential delays in large order finalization and integration challenges at recently acquired Ideal Explosives.

Risks4 trackedTranscriptfull text
Research workspace

Focused Modules

Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

Order Book ₹800 crore
flat

Order book as of September end; additional orders received in Oct-Nov.

Unit 3 Capacity Expansion 8x
flat

New facility will increase production capacity eightfold vs current.

Production Revenue Mix 25-35%
flat

Current share of production in revenue; expected to rise to 40-45%.

Export Opportunity Pipeline ₹100 crore
flat

Export orders under development, including a UK order of ₹113 crore.

Fast read

Guidance and risk preview

Top guidance Revenue CAGR of 45-50% over FY26-27

Core business growth excluding acquisition, driven by order book and production ramp-up.

Top risk Large order delays

MIGM and QRSAM orders may slip beyond March; management expects by Q1 FY27 at latest.

View Risks →